Literature DB >> 29102079

Early onset facioscapulohumeral dystrophy - a systematic review using individual patient data.

Rianne J M Goselink1, Nicol C Voermans2, Kees Okkersen2, Oebele F Brouwer3, George W Padberg2, Ana Nikolic4, Rossella Tupler5, Malgorzata Dorobek6, Jean K Mah7, Baziel G M van Engelen2, Tim H A Schreuder2, Corrie E Erasmus2.   

Abstract

Infantile or early onset is estimated to occur in around 10% of all facioscapulohumeral dystrophy (FSHD) patients. Although small series of early onset FSHD patients have been reported, comprehensive data on the clinical phenotype is missing. We performed a systematic literature search on the clinical features of early onset FSHD comprising a total of 43 articles with individual data on 227 patients. Additional data from four cohorts was provided by the authors. Mean age at reporting was 18.8 years, and 40% of patients were wheelchair-dependent at that age. Half of the patients had systemic features, including hearing loss (40%), retinal abnormalities (37%) and developmental delay (8%). We found an inverse correlation between repeat size and disease severity, similar to adult-onset FSHD. De novo FSHD1 mutations were more prevalent than in adult-onset FSHD. Compared to adult FSHD, our findings indicate that early onset FSHD is overall characterized by a more severe muscle phenotype and a higher prevalence of systemic features. However, similar as in adults, a significant clinical heterogeneity was observed. Based on this, we consider early onset FSHD to be on the severe end of the FSHD disease spectrum. We found natural history studies and treatment studies to be very scarce in early onset FSHD, therefore longitudinal studies are needed to improve prognostication, clinical management and trial-readiness.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Early onset; Facioscapulohumeral dystrophy; Infantile FSHD

Mesh:

Year:  2017        PMID: 29102079     DOI: 10.1016/j.nmd.2017.09.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  16 in total

1.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

2.  Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Authors:  Jonathan Oliva; Scott Galasinski; Amelia Richey; Amy E Campbell; Marvin J Meyers; Neal Modi; Jun Wen Zhong; Rabi Tawil; Stephen J Tapscott; Francis M Sverdrup
Journal:  J Pharmacol Exp Ther       Date:  2019-06-12       Impact factor: 4.030

Review 3.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 4.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

5.  DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.

Authors:  Kenji Rowel Q Lim; Adam Bittel; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Yiqing Huang; Kasia Dzierlega; Aiping Zhang; Yi-Wen Chen; Toshifumi Yokota
Journal:  Mol Ther       Date:  2020-10-15       Impact factor: 11.454

6.  Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  Allison Ducharme-Smith; Stefan Nicolau; C Anwar A Chahal; Kirstie Ducharme-Smith; Shujah Rehman; Keerthi Jaliparthy; Nadeem Khan; Christopher G Scott; Erik K St Louis; Teerin Liewluck; Virend K Somers; Grace Lin; Peter A Brady; Margherita Milone
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

Review 7.  Facioscapulohumeral muscular dystrophy-Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease.

Authors:  Sanne C C Vincenten; Nienke Van Der Stoep; Aimée D C Paulussen; Karlien Mul; Umesh A Badrising; Marjolein Kriek; Olivier W H Van Der Heijden; Baziel G M Van Engelen; Nicol C Voermans; Christine E M De Die-Smulders; Saskia Lassche
Journal:  Clin Genet       Date:  2021-08-01       Impact factor: 4.296

8.  Counseling and prenatal diagnosis in facioscapulohumeral muscular dystrophy: A retrospective study on a 13-year multidisciplinary approach.

Authors:  Maria Francesca Di Feo; Cinzia Bettio; Valentina Salsi; Emma Bertucci; Rossella Tupler
Journal:  Health Sci Rep       Date:  2022-04-20

9.  The French National Registry of patients with Facioscapulohumeral muscular dystrophy.

Authors:  Céline Guien; Gaëlle Blandin; Pauline Lahaut; Benoît Sanson; Katia Nehal; Sitraka Rabarimeriarijaona; Rafaëlle Bernard; Nicolas Lévy; Sabrina Sacconi; Christophe Béroud
Journal:  Orphanet J Rare Dis       Date:  2018-12-04       Impact factor: 4.123

10.  Facioscapulohumeral Dystrophy in Childhood: A Nationwide Natural History Study.

Authors:  Rianne J M Goselink; Tim H A Schreuder; Nens van Alfen; Imelda J M de Groot; Merel Jansen; Richard J L F Lemmers; Patrick J van der Vliet; Nienke van der Stoep; Thomas Theelen; Nicol C Voermans; Silvère M van der Maarel; Baziel G M van Engelen; Corrie E Erasmus
Journal:  Ann Neurol       Date:  2018-10-16       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.